Mepolizumab as the first targeted treatment for eosinophilic granulomatosis with polyangiitis: a review of current evidence and potential place in therapy

References

• VarricchiGBagnascoDFerrandoMPuggioniFPassalacquaGCanonicaGWMepolizumab in the management of severe eosinophilic asthma in adults: current evidence and practical experienceTher Adv Respir Dis2017111404527856823
   PubMed Web of Science ®Google Scholar
• WechslerMEAkuthotaPKhouryPNovel Treatments for Airway DiseaseN Engl J Med20173776597598
   Google Scholar
• ChurgJStraussLAllergic granulomatosis, allergic angiitis, and peri-arteritis nodosaAm J Pathol195127227730114819261
   PubMed Web of Science ®Google Scholar
• LanhamJGElkonKBPuseyCDHughesGRSystemic vasculitis with asthma and eosinophilia: a clinical approach to the Churg-Strauss syndromeMedicine198463265816366453
   PubMed Web of Science ®Google Scholar
• MasiATHunderGGLieJTThe American College of Rheumatology 1990 criteria for the classification of Churg-Strauss syndrome (allergic granulomatosis and angiitis)Arthritis Rheum1990338109411002202307
   PubMed Web of Science ®Google Scholar
• WattsRLaneSHanslikTDevelopment and validation of a consensus methodology for the classification of the ANCA-associated vasculitides and polyarteritis nodosa for epidemiological studiesAnn Rheum Dis200766222222716901958
   PubMed Web of Science ®Google Scholar
• SinicoRABotteroPChurg-Strauss angiitisBest Pract Res Clin Rheumatol200923335536619508943
   PubMed Web of Science ®Google Scholar
• JennetteJCFalkRJAndrassyKNomenclature of systemic vasculitides. Proposal of an international consensus conferenceArthritis Rheum19943721871928129773
   PubMed Web of Science ®Google Scholar
• JennetteJCFalkRJBaconPA2012 Revised International Chapel Hill Consensus Conference Nomenclature of VasculitidesArthritis & Rheumatism201365111123045170
   PubMed Web of Science ®Google Scholar
• ComarmondCPagnouxCKhellafMEosinophilic granulomatosis with polyangiitis (Churg-Strauss): clinical characteristics and long-term followup of the 383 patients enrolled in the French Vasculitis Study Group cohortArthritis Rheum201365127028123044708
   PubMed Web of Science ®Google Scholar
• SinicoRAdi TomaLMaggioreUPrevalence and clinical significance of antineutrophil cytoplasmic antibodies in Churg-Strauss syndromeArthritis Rheum20055292926293516142760
   PubMed Web of Science ®Google Scholar
• TsukadairaAOkuboYKitanoKEosinophil active cytokines and surface analysis of eosinophils in Churg-Strauss syndromeAllergy Asthma Proc1999201394410076708
   PubMed Web of Science ®Google Scholar
• KouroTTakatsuKIL-5- and eosinophil-mediated inflammation: from discovery to therapyInt Immunol200921121303130919819937
   PubMed Web of Science ®Google Scholar
• Sablé-FourtassouRCohenPMahrAAntineutrophil cytoplasmic antibodies and the Churg-Strauss syndromeAnn Intern Med2005143963263816263885
   PubMed Web of Science ®Google Scholar
• AbrilAChurg-strauss syndrome: an updateCurr Rheumatol Rep201113648949521863326
   PubMed Web of Science ®Google Scholar
• SimonHURothenbergMEBochnerBSRefining the definition of hypereosinophilic syndromeJ Allergy Clin Immunol20101261454920639008
   PubMed Web of Science ®Google Scholar
• ValentPKlionADHornyHPContemporary consensus proposal on criteria and classification of eosinophilic disorders and related syndromesJ Allergy Clin Immunol2012130360761222460074
   PubMed Web of Science ®Google Scholar
• GuillevinLCohenPGayraudMLhoteFJarrousseBCasassusPChurg-Strauss syndrome. Clinical study and long-term follow-up of 96 patientsMedicine199978126379990352
   PubMed Web of Science ®Google Scholar
• VaglioAMartoranaDMaggioreUHLA-DRB4 as a genetic risk factor for Churg-Strauss syndromeArthritis Rheum20075693159316617763415
   PubMed Web of Science ®Google Scholar
• WieczorekSHellmichBArningLFunctionally relevant variations of the interleukin-10 gene associated with antineutrophil cytoplasmic antibody-negative Churg-Strauss syndrome, but not with Wegener’s granulomatosisArthritis Rheum20085861839184818512809
   PubMed Web of Science ®Google Scholar
• WieczorekSHellmichBGrossWLEpplenJTAssociations of Churg-Strauss syndrome with the HLA-DRB1 locus, and relationship to the genetics of antineutrophil cytoplasmic antibody-associated vasculitides: comment on the article by Vaglio et alArthritis Rheum200858132933018163478
   PubMed Web of Science ®Google Scholar
• SchmittWHCsernokEKobayashiSKlinkenborgAReinhold-KellerEGrossWLChurg-Strauss syndrome: serum markers of lymphocyte activation and endothelial damageArthritis Rheum19984134454529506572
   PubMed Web of Science ®Google Scholar
• GuidaGVallarioAStellaSClonal CD8+ TCR-Vbeta expanded populations with effector memory phenotype in Churg Strauss syndromeClin Immunol200812819410218502180
   PubMed Web of Science ®Google Scholar
• GuillevinLAmourouxJArbeilleBBouraRChurg-Strauss angiitis. Arguments favoring the responsibility of inhaled antigensChest19911005147214731935321
   PubMed Web of Science ®Google Scholar
• DietzAHübnerCAndrassyKMacrolide antibiotic-induced vasculitis (Churg-Strauss syndrome)Laryngorhinootologie19987721111149555706
   PubMed Web of Science ®Google Scholar
• ImaiHNakamotoYHirokawaMAkihamaTMiuraABCarbamazepine-induced granulomatous necrotizing angiitis with acute renal failureNephron19895134054082918954
   PubMed Web of Science ®Google Scholar
• MathurSDooleyJScheuerPJQuinine induced granulomatous hepatitis and vasculitisBMJ19903006724613
   Web of Science ®Google Scholar
• GuillevinLGuittardTBletryOGodeauPRosenthalPSystemic necrotizing angiitis with asthma: causes and precipitating factors in 43 casesLung198716531651723108593
   PubMed Web of Science ®Google Scholar
• BibbySHealyBSteeleRKumareswaranKNelsonHBeasleyRAssociation between leukotriene receptor antagonist therapy and Churg-Strauss syndrome: an analysis of the FDA AERS databaseThorax2010652132138
   PubMed Web of Science ®Google Scholar
• Gómez-PuertaJAGedmintasLCostenbaderKHThe association between silica exposure and development of ANCA-associated vasculitis: systematic review and meta-analysisAutoimmun Rev201312121129113523820041
   PubMed Web of Science ®Google Scholar
• KostianovskyACharlesPAlvesJFImmunogenicity and safety of seasonal and 2009 pandemic A/H1N1 influenza vaccines for patients with autoimmune diseases: a prospective, monocentre trial on 199 patientsClin Exp Rheumatol2012301 Suppl 70S83S8922640652
   PubMed Web of Science ®Google Scholar
• WechslerMEWongDAMillerMKLawrence-MiyasakiLChurgstrauss syndrome in patients treated with omalizumabChest2009136250751819411292
   PubMed Web of Science ®Google Scholar
• GreenRLVayonisAGChurg-Strauss syndrome after zafirlukast in two patients not receiving systemic steroid treatmentThe Lancet19993539154725726
   Web of Science ®Google Scholar
• WechslerMEFinnDGunawardenaDChurg-Strauss syndrome in patients receiving montelukast as treatment for asthmaChest2000117370871310712995
   PubMed Web of Science ®Google Scholar
• PuéchalXRivereauPVinchonFChurg-Strauss syndrome associated with omalizumabEur J Intern Med200819536436618549941
   PubMed Web of Science ®Google Scholar
• HauserTMahrAMetzlerCThe leucotriene receptor antagonist montelukast and the risk of Churg-Strauss syndrome: a case-crossover studyThorax200863867768218276721
   PubMed Web of Science ®Google Scholar
• KhouryPGraysonPCKlionADEosinophils in vasculitis: characteristics and roles in pathogenesisNat Rev Rheumatol201410847448325003763
   PubMed Web of Science ®Google Scholar
• SaitoHTsurikisawaNTsuburaiTOshikataCAkiyamaKThe proportion of regulatory T cells in the peripheral blood reflects the relapse or remission status of patients with Churg-Strauss syndromeInt Arch Allergy Immunol2011155Suppl 1465221646795
   PubMed Web of Science ®Google Scholar
• KieneMCsernokEMüllerAMetzlerCTrabandtAGrossWLElevated interleukin-4 and interleukin-13 production by T cell lines from patients with Churg-Strauss syndromeArthritis Rheum200144246947311229479
   PubMed Web of Science ®Google Scholar
• DunoguéBPagnouxCGuillevinLChurg-strauss syndrome: clinical symptoms, complementary investigations, prognosis and outcome, and treatmentSemin Respir Crit Care Med201132329830921674415
   PubMed Web of Science ®Google Scholar
• JakielaBSanakMSzczeklikWBoth Th2 and Th17 responses are involved in the pathogenesis of Churg-Strauss syndromeClin Exp Rheumatol2011291 Suppl 64S23S34
   PubMed Web of Science ®Google Scholar
• JakielaBSzczeklikWPluteckaHIncreased production of IL-5 and dominant Th2-type response in airways of Churg-Strauss syndrome patientsRheumatology201251101887189322772323
   PubMed Web of Science ®Google Scholar
• MoosigFGrossWLHerrmannKBremerJPHellmichBTargeting interleukin-5 in refractory and relapsing Churg-Strauss syndromeAnn Intern Med2011155534134321893636
   PubMed Web of Science ®Google Scholar
• TerrierBBiècheIMaisonobeTInterleukin-25: a cytokine linking eosinophils and adaptive immunity in Churg-Strauss syndromeBlood2010116224523453120729468
   PubMed Web of Science ®Google Scholar
• VaglioAMoosigFZwerinaJChurg-Strauss syndrome: update on pathophysiology and treatmentCurr Opin Rheumatol2012241243022089097
   PubMed Web of Science ®Google Scholar
• MahrAGuillevinLPoissonnetMAyméSPrevalences of polyarteritis nodosa, microscopic polyangiitis, Wegener’s granulomatosis, and Churg-Strauss syndrome in a French urban multiethnic population in 2000: A capture-recapture estimateArthritis Care Res20045119299
   Web of Science ®Google Scholar
• WattsRALaneSEBenthamGScottDGEpidemiology of systemic vasculitis: a ten-year study in the United KingdomArthritis Rheum200043241441910693883
   PubMed Web of Science ®Google Scholar
• ZwerinaJBachCMartoranaDEotaxin-3 in Churg-Strauss syndrome: a clinical and immunogenetic studyRheumatology201150101823182721266446
   PubMed Web of Science ®Google Scholar
• PolzerKKaronitschTNeumannTEotaxin-3 is involved in Churg-Strauss syndrome – a serum marker closely correlating with disease activityRheumatology200847680480818397958
   PubMed Web of Science ®Google Scholar
• BaldiniCTalaricoRdella RossaABombardieriSClinical manifestations and treatment of Churg-Strauss syndromeRheum Dis Clin North Am201036352754320688248
   PubMed Web of Science ®Google Scholar
• VaglioAStrehlJDMangerBIgG4 immune response in Churg-Strauss syndromeAnn Rheum Dis201271339039322121132
   PubMed Web of Science ®Google Scholar
• Ramentol-SintasMMartínez-ValleFSolans-LaquéRChurg-Strauss Syndrome: an evolving paradigmAutoimmun Rev201212223524022796280
   PubMed Web of Science ®Google Scholar
• ChurgARecent advances in the diagnosis of Churg-Strauss syndromeMod Pathol200114121284129311743052
   PubMed Web of Science ®Google Scholar
• TsurikisawaNSaitoHTsuburaiTDifferences in regulatory T cells between Churg-Strauss syndrome and chronic eosinophilic pneumonia with asthmaJ Allergy Clin Immunol2008122361061618586318
   PubMed Web of Science ®Google Scholar
• LepseNAbdulahadWHKallenbergCGHeeringaPImmune regulatory mechanisms in ANCA-associated vasculitidesAutoimmun Rev2011112778321856453
   PubMed Web of Science ®Google Scholar
• FreeMEBunchDOMcgregorJAPatients with antineutrophil cytoplasmic antibody-associated vasculitis have defective Treg cell function exacerbated by the presence of a suppression-resistant effector cell populationArthritis Rheum20136571922193323553415
   PubMed Web of Science ®Google Scholar
• VaglioACasazzaIGrasselliCCorradiDSinicoRABuzioCChurg-Strauss syndromeKidney Int20097691006101119516244
   PubMed Web of Science ®Google Scholar
• FalkRJTerrellRSCharlesLAJennetteJCAnti-neutrophil cytoplasmic autoantibodies induce neutrophils to degranulate and produce oxygen radicals in vitroProc Natl Acad Sci U S A19908711411541192161532
   PubMed Web of Science ®Google Scholar
• XiaoHHeeringaPHuPAntineutrophil cytoplasmic autoantibodies specific for myeloperoxidase cause glomerulonephritis and vasculitis in miceJ Clin Invest2002110795596312370273
   PubMed Web of Science ®Google Scholar
• Flood-PagePTMenzies-GowANKayABRobinsonDSEosinophil’s role remains uncertain as anti-interleukin-5 only partially depletes numbers in asthmatic airwayAm J Respir Crit Care Med2003167219920412406833
   PubMed Web of Science ®Google Scholar
• Flood-PagePSwensonCFaifermanIA study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthmaAm J Respir Crit Care Med2007176111062107117872493
   PubMed Web of Science ®Google Scholar
• Menzies-GowAFlood-PagePSehmiRAnti-IL-5 (mepolizumab) therapy induces bone marrow eosinophil maturational arrest and decreases eosinophil progenitors in the bronchial mucosa of atopic asthmaticsJ Allergy Clin Immunol2003111471471912704348
   PubMed Web of Science ®Google Scholar
• HaldarPBrightlingCEHargadonBMepolizumab and exacerbations of refractory eosinophilic asthmaN Engl J Med20093601097398419264686
   PubMed Web of Science ®Google Scholar
• ChuppGLBradfordESAlbersFCEfficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trialLancet Respir Med20175539040028395936
   PubMed Web of Science ®Google Scholar
• NairPPizzichiniMMKjarsgaardMMepolizumab for prednisone-dependent asthma with sputum eosinophiliaN Engl J Med20093601098599319264687
   PubMed Web of Science ®Google Scholar
• PavordIDKornSHowarthPMepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trialLancet2012380984265165922901886
   PubMed Web of Science ®Google Scholar
• OrtegaHGLiuMCPavordIDMepolizumab treatment in patients with severe eosinophilic asthmaN Engl J Med Overseas Ed20143711311981207
   PubMed Web of Science ®Google Scholar
• BelEHWenzelSEThompsonPJOral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthmaN Engl J Med2014371131189119725199060
   PubMed Web of Science ®Google Scholar
• SpadaroGPecoraroAde RenzoAdella PepaRGenoveseAIntravenous versus subcutaneous immunoglobulin replacement in secondary hypogammaglobulinemiaClin Immunol2016166–167103104
   PubMed Web of Science ®Google Scholar
• KallurLGonzalez-EstradaAEidelmanFDimovVPharmacokinetic drug evaluation of mepolizumab for the treatment of severe asthma associated with persistent eosinophilic inflammation in adultsExpert Opin Drug Metab Toxicol201713121275128029157020
   PubMed Web of Science ®Google Scholar
• DasguptaAKjarsgaardMCapaldiDA pilot randomised clinical trial of mepolizumab in COPD with eosinophilic bronchitisEur Respir J2017493160248628298405
   PubMed Web of Science ®Google Scholar
• PavordIDChanezPCrinerGJMepolizumab for eosinophilic chronic obstructive pulmonary diseaseN Engl J Med Overseas Ed20173771716131629
   PubMed Web of Science ®Google Scholar
• SteinMLVillanuevaJMBuckmeierBKAnti–IL-5 (mepolizumab) therapy reduces eosinophil activation ex vivo and increases IL-5 and IL-5 receptor levelsJ Allergy Clin Immunol200812161473148318410960
   PubMed Web of Science ®Google Scholar
• SteinMLCollinsMHVillanuevaJMAnti-IL-5 (mepolizumab) therapy for eosinophilic esophagitisJ Allergy Clin Immunol200611861312131917157662
   PubMed Web of Science ®Google Scholar
• PlötzS-GSimonH-UDarsowUUse of an Anti–Interleukin-5 Antibody in the Hypereosinophilic Syndrome with Eosinophilic DermatitisN Engl J Med Overseas Ed20033492423342339
   Web of Science ®Google Scholar
• RothenbergMEKlionADRoufosseFETreatment of Patients with the Hypereosinophilic Syndrome with MepolizumabN Engl J Med Overseas Ed20083581212151228
   PubMed Web of Science ®Google Scholar
• KuangFLFayMPWareJLong-term clinical outcomes of high-dose mepolizumab treatment for hypereosinophilic syndromeJ Allergy Clin Immunol Pract2018651518152729751154
   PubMed Web of Science ®Google Scholar
• RoufosseFEKahnJ-EGleichGJLong-term safety of mepolizumab for the treatment of hypereosinophilic syndromesJ Allergy Clin Immunol20131312461e14675e123040887
   PubMed Web of Science ®Google Scholar
• KahnJ-EGrandpeix-GuyodoCMarrounISustained response to mepolizumab in refractory Churg-Strauss syndromeJ Allergy Clin Immunol2010125126727020109753
   PubMed Web of Science ®Google Scholar
• HerrmannKGrossWLMoosigFExtended follow-up after stopping mepolizumab in relapsing/refractory Churg-Strauss syndromeClin Exp Rheumatol2012301 Suppl 70S62S65
   PubMed Web of Science ®Google Scholar
• WechslerMEAkuthotaPJayneDMepolizumab or placebo for eosinophilic granulomatosis with polyangiitisN Engl J Med Overseas Ed20173762019211932
   PubMed Web of Science ®Google Scholar
• KimSMarigowdaGOrenEIsraelEWechslerMEMepolizumab as a steroid-sparing treatment option in patients with Churg-Strauss syndromeJ Allergy Clin Immunol201012561336134320513524
   PubMed Web of Science ®Google Scholar
• FarneHAWilsonAPowellCBaxLMilanSJAnti-IL5 therapies for asthmaCochrane Airways GroupCochrane Database Syst Rev [cited 2018 July 29]. Available from: http://doi.wiley.com/10.1002/14651858.CD010834.pub3Accessed date: September 21, 2017
   Google Scholar
• GuillevinLVasculitis: Mepolizumab for eosinophilic granulomatosis with polyangiitisNat Rev Rheumatol201713951851928769112
   PubMed Web of Science ®Google Scholar
• RoufosseFTargeting the interleukin-5 pathway for treatment of eosinophilic conditions other than asthmaFront Med2018549
   PubMed Web of Science ®Google Scholar
• ThompsonGVasilevskiNRyanMBalticSThompsonPLow-dose mepolizumab effectively treats chronic relapsing eosinophilic granulomatosis with polyangiitisRespirologySupplement: The Australia & New Zealand Society of Respiratory Science and The Thoracic Society of Australia and New Zealand (ANZSRS/TSANZ) Annual Scientific MeetingAdelaide, Australia23–27 March 2018201823Suppl 1178
   Google Scholar